Effect of pediatric- versus adult-type chemotherapy regimens on outcomes of allogeneic hematopoietic stem cell transplants for adult T-cell acute lymphoblastic leukemia in first complete remission.

ABSTRACT

The optimal chemotherapy regimen pre-transplantation for adult T-cell acute lymphoblastic leukemia (T-ALL) patients remains unknown. Here, we compared the transplant outcomes in 127 subjects receiving pediatric- (N = 57) or adult-type (N = 70) regimens pre-transplant. The corresponding 3-year cumulative incidences of relapse (CIR) was 7% (95% CI 3-11%) and 29% (95% CI 23-35%; P = 0.02), leukemia-free survivals (LFS) was 86% (95% CI 81-91%) and 57% (95% CI 51-63%; P = 0.003), overall survivals (OS) was 88% (95% CI 84-92%) and 58% (95% CI 52-64%; P = 0.002), the 1-year NRM was 4% (95% CI 1-7%) and 9% (95% CI 4-14%; P = 0.40). Multivariate analysis showed that pediatric-type regimen was associated with lower CIR (Hazard Ratio [HR] = 0.31 [95% CI 0.09-1.00]; P = 0.05), better LFS (HR = 0.34 [95% CI 0.15-0.78]; P = 0.01) and OS (HR = 0.30 [95% CI 0.13-0.72]; P = 0.01). Our results suggested that adult T-ALL patients undergoing allo-HSCT might benefit from pediatric-type chemotherapy.